Elvitegravir

Drug Profile

Elvitegravir

Alternative Names: GS-9137; JTK-303; Vitekta

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Gilead Sciences; Japan Tobacco
  • Class Antiretrovirals; Quinolones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered HIV-1 infections

Most Recent Events

  • 14 May 2015 Elvitegravir is still in phase III trials for HIV-1 infections (Combination therapy, Treatment-experienced) in Puerto Rico, Mexico and Switzerland
  • 01 Apr 2015 Gilead completes a phase III trial in HIV infections in Australia, Canada, England, Mexico, Puerto Rico, Scotland, Switzerland, USA and European Union (NCT00708162)
  • 25 Nov 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top